Omkar Speciality Chemicals Ltd

Omkar Spl.Chem. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Omkar Speciality Chemicals Ltd

₹ 3.60 -4.76%
28 Apr 1:54 p.m.
omkarchemicals.com BSE: 533317 NSE: OMKARCHEM
About

Incorporated in 1993, Omkar Specialty Chemicals Ltd is a global specialty chemicals company.[1]

Key Points

Business Overview:[1][2]
a) OSCL manufactures specialty chemicals and pharma intermediates like organic and inorganic chemicals, and organo-inorganic intermediates.
b) The Inorganic Intermediates include Molybdenum derivatives, Selenium derivatives, Iodine derivatives, Cobalt derivatives, Bismuth & Tungsten derivatives, and organic intermediates include Tartaric acid derivatives and other intermediates.
c) The pharmaceutical industry remains the major end user segment of the company, accounting for nearly 70-75% of its revenues, with poultry, glass, and water treatment being the other major end user segments.

Website BSE NSE - BZ
  • Market Cap ₹ 7.41 Cr.
  • Current Price ₹ 3.60
  • High / Low ₹ 8.10 / 3.35
  • Stock P/E 0.20
  • Book Value ₹ 106
  • Dividend Yield 0.00 %
  • ROCE 18.0 %
  • ROE 17.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.03 times its book value

Cons

  • Contingent liabilities of Rs.111 Cr.
  • Dividend payout has been low at 14.8% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2013 Mar 2014 Jun 2014 Sep 2014 Dec 2014 Mar 2015 Jun 2015 Sep 2015 Dec 2015 Mar 2016 Jun 2016 Sep 2016 Dec 2016
54 74 54 67 71 74 90 101 108 113 113 129 126
43 62 45 53 55 60 73 83 91 86 89 104 101
Operating Profit 10 12 9 13 16 14 17 18 18 28 23 25 25
OPM % 20% 16% 16% 20% 23% 19% 19% 18% 16% 25% 21% 20% 20%
0 2 0 0 0 0 0 0 0 0 1 1 1
Interest 4 4 3 4 4 4 4 4 4 8 6 7 6
Depreciation 2 4 1 1 1 7 2 2 2 3 4 4 5
Profit before tax 5 6 5 9 11 3 12 12 12 16 15 15 15
Tax % 27% 47% 4% 27% 32% -61% 33% 25% 20% 76% 26% 24% 29%
3 3 5 6 7 5 8 9 9 4 11 12 11
EPS in Rs 1.69 1.69 2.54 3.11 3.64 2.63 3.97 4.37 4.56 1.96 5.33 5.61 5.10
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 TTM
107 167 212 240 265 413 481
85 134 172 197 213 333 380
Operating Profit 21 33 40 43 52 81 101
OPM % 20% 20% 19% 18% 20% 20% 21%
1 3 4 3 1 1 2
Interest 5 8 8 14 14 20 26
Depreciation 2 6 7 12 10 9 16
Profit before tax 15 23 30 20 28 52 61
Tax % 31% 29% 32% 31% 14% 42%
10 16 21 14 24 31 37
EPS in Rs 5.19 8.16 10.49 6.92 11.79 14.86 18.00
Dividend Payout % 19% 15% 14% 22% 13% 10%
Compounded Sales Growth
10 Years: %
5 Years: 31%
3 Years: 25%
TTM: 29%
Compounded Profit Growth
10 Years: %
5 Years: 25%
3 Years: 15%
TTM: 17%
Stock Price CAGR
10 Years: -27%
5 Years: -21%
3 Years: -22%
1 Year: -40%
Return on Equity
10 Years: %
5 Years: 15%
3 Years: 15%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Sep 2016
Equity Capital 20 20 20 20 21 21 21
Reserves 73 86 107 118 148 175 198
46 99 151 206 224 228 230
35 33 51 59 87 159 151
Total Liabilities 173 237 329 403 479 583 599
22 39 92 91 149 161 338
CWIP 18 60 44 97 122 149 0
Investments 0 0 0 0 0 0 0
133 138 192 215 208 273 261
Total Assets 173 237 329 403 479 583 599

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016
-14 11 -9 29 81 67
-25 -63 -42 -61 -94 -46
80 43 43 30 10 -26
Net Cash Flow 41 -9 -9 -2 -3 -5
Free Cash Flow -39 -53 -52 -34 -13 21
CFO/OP -54% 50% -8% 84% 155% 83%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016
Debtor Days 93 84 114 143 106 115
Inventory Days 148 168 190 191 193 126
Days Payable 105 80 95 102 134 124
Cash Conversion Cycle 136 173 209 232 165 117
Working Capital Days 70 3 39 -5 -77 -15
ROCE % 18% 16% 11% 12% 18%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 May 2025
Registered Process Patents
Number

Log in to view insights

Please log in to see hidden values.

Login
Total Rated Capacity
TPA
Total Volumetric Capacity
MTPA
Actual Production Volume
MT
Capacity Utilisation
%
Number of Manufacturing Units
Number
Export Contribution to Revenue
%
Number of In-house Products
Number
Drug Master Files (DMFs) Prepared
Number
Patent Applications Pending
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022
27.62% 27.62% 27.62% 27.62% 27.62% 27.62% 14.71% 27.62% 17.62% 17.62% 14.71% 14.71%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.06% 0.00% 0.01% 0.00% 0.06% 0.06%
0.01% 0.03% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.01% 0.01% 0.01%
72.38% 72.35% 72.38% 72.38% 72.38% 72.38% 85.22% 72.38% 82.36% 82.37% 85.22% 85.22%
No. of Shareholders 19,72819,50719,08718,96518,67818,27319,43017,46119,15219,31819,43019,430

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls